Justin Ezekowitz, ACC 2022: SODIUM-HF: Study of dietary intervention under 100 Mmol in heart failure
The SODIUM-HF trial tested whether or not a reduction in dietary sodium reduces the incidence of heart failure. touchCARDIO speaks with Prof. Justin Ezekowitz (University of Alberta, Edmonton, Canada) to discuss his presentation on the SODIUM-HF study on the effect of sodium restriction on mortality and morbidity in patients with heart failure.
The presentation entitled ‘SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure’ was presented at the American College of Cardiology Annual Meeting 2022, April 02-04, 2022
- What is currently known about the effect of sodium restriction on mortality and morbidity in patients with heart failure? (00:23)
- What were the aims and design of the SODIUM-HF study? (01:04)
- What were the primary and secondary endpoints, and how well were they achieved? (02:18)
- Which patients were most likely to benefit from this intervention? (04:25)
- On the basis of these findings, what are your recommendations for clinical practice, and what further research is needed? (05:57)
Disclosures: Justin Ezekowitz is a consultant for American Regent, Amgen, AstraZeneca, Bayer, Bristol-Meyers Squibb, Merck, Sanofi and Servier and received grants/research support from American Regent, Amgen, AstraZeneca, Bayer, Bristol-Meyers Squibb, Merck, Sanofi, Servier, Ortho-Biotech/Johnson & Johnson and Eko
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!